|本期目录/Table of Contents|

[1]张瑞宁,魏 芳,王立华,等.碳酸镧治疗维持性血液透析高磷血症患者疗效观察[J].天津医科大学学报,2014,20(04):303-305.
点击复制

碳酸镧治疗维持性血液透析高磷血症患者疗效观察(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
20卷
期数:
2014年04期
页码:
303-305
栏目:
临床医学
出版日期:
2014-07-08

文章信息/Info

Title:
-
文章编号:
1006-8147（2014）04-0303-03
作者:
张瑞宁; 魏 芳; 王立华; 姜埃利
（天津医科大学第二医院血液净化中心，天津 300211）
Author(s):
-
关键词:
维持性血液透析; 高磷血症; 碳酸镧
Keywords:
-
分类号:
R692
DOI:
-
文献标志码:
A
摘要:
目 的：观察碳酸镧治疗维持性血液透析（MHD）高磷血症患者的短期疗效及不良反应。方法：对31例MHD高磷血症患者使用福斯利诺治疗，用药前及用药后1 月检测血磷（P）、钙（Ca）、甲状旁腺素（PTH）、白蛋白（Alb）及血红蛋白（Hb），评价治疗效果；观察有无不良反应。结果：（1）用药后1 月患者血P较治疗前下降，差异有统计学意义(P＜0.05)；血Ca、PTH、Alb及Hb治疗前后差异无统计学意义（P＞0.05）。（2）31例患者达标3例，好转18例，有效21例，总有效率为67.7%，无效9例，不良反应1例。结论：碳酸镧用于短期治疗MHD患者的高磷血症有效且耐受性良好，但仍需严密观察其不良反应。
Abstract:
-

参考文献/References:

[1] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815

[2] Hoshina M, Wada H, Sakakura K, et al. Determinants of progression of aortic valve stenosis and outcome of adverse events in hemodialysis patients[J]. J Cardiol, 2012, 59(1): 78

[3] Noordzij M, Cranenburg E M, Engelsman L F, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients[J]. Nephrol Dial Transplant, 2011, 26(5), 1662

[4] Palmer S C, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis[J]. JAMA, 2011, 305(11): 1119

[5] Danese M D, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients[J]. Clin J Am Soc Nephrol, 2008, 3(5): 1423

[6] Nikolov I G, Joki N, Nguyen-Khoa T, et al. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice[J]. Nephrol Dial Transplant,2012, 27(2): 505

[7] Vemuri N, Michelis M F, Matalon A. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study[J]. BMC Nephrol, 2011, 12: 49

[8] Goto S, Komaba H, Moriwakiet K, et al. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1375

[9] Shigematsu T, Tokumoto A, Nakaoka A, et al. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia[J]. Ther Apher Dial, 2011, 15( 2) : 176

[10] Toussaint N D, Lau K K, Polkinghorne K R, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial[J]. Nephrology, 2011, 16(3): 290

相似文献/References:

[1]孟 甲,魏 芳,王立华,等.终末期肾病血液透析相关性腹水发生情况及其相关危险因素的探讨[J].天津医科大学学报,2017,23(02):112.
[2]陈亚巍,孙新增,张 萍,等.非糖尿病SHPT血液透析患者行PTX+AT对钙磷代谢和胰岛素分泌的影响[J].天津医科大学学报,2018,24(06):532.
　CHEN Ya-wei,SUN Xin-zeng,ZHANG Ping,et al.Effects of parathyroidectomy with autotransplantation on calcium- phosphorus disorder and insulin secretion in non-diabetic uremic patients with SHPT[J].Journal of Tianjin Medical University,2018,24(04):532.
[3]李丽,刘欣.维持性血液透析患者体液分布情况与营养状况的关系[J].天津医科大学学报,2021,27(02):159.
　LI Li,LIU Xin.The relationship between body fluid distribution and nutritional status in maintenance hemodialysis patients[J].Journal of Tianjin Medical University,2021,27(04):159.

备注/Memo

备注/Memo:

基金项目 天津市医药卫生2012年度重点攻关项目基金资助（12KG136）

作者简介 张瑞宁（1982-），女，医师，硕士，研究方向：肾脏病血液净化；通信作者：魏芳，E-mail：weiwei258@vip.sina.com。

更新日期/Last Update: 2014-06-06